Evidence map›Paper›PMID 41876608›Full record

ArticleScientific reports2026

A lasso-based model combining miRNA and clinical variables predicts future risk of breast and ovarian cancer.

James W Webber, Laura Wollborn, Sudhanshu Mishra, Stephanie Alimena, Bryanna Testino, Konrad Stawiski, Wojciech Fendler, Dipanjan Chowdhury, Kevin M Elias

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

James W WebberDepartment of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Laura WollbornDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, USA.
Sudhanshu MishraDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, USA.
Stephanie AlimenaDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, USA.
Bryanna TestinoDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, USA.
Konrad StawiskiDepartment of Biostatistics and Translational Medicine, Medical University of Łódź, Łódź, Poland.
Wojciech FendlerDepartment of Biostatistics and Translational Medicine, Medical University of Łódź, Łódź, Poland.
Dipanjan ChowdhuryHarvard Medical School, Boston, MA, USA.
Kevin M EliasDepartment of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. eliask2@ccf.org.

Funding

Project 2: Combined personal neoantigen-targeting cancer vaccines with immune checkpoint blockade for ovarian cancerP50CA240243 · NCI · DANA-FARBER CANCER INST · PI CASTRO, CESAR M · 2020 to 2024
$11.5M
Ovarian cancer risk stratification using circulating miRNAs to assess BRCAnessR03CA283252 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIAS, KEVIN · 2023 to 2023
$116k
Deutsche Forschungsgemeinschaft 450518177NCI NIH HHS b. 1R03CA283252-01NCI NIH HHS P50CA240243NCI NIH HHS R03 CA283252
6 · The paper itself

Abstract

Hereditary breast and ovarian cancer syndrome (HBOC) is principally caused by germline mutations in BRCA1 and BRCA2. However, most women with HBOC are undiagnosed, and some patients meeting clinical criteria for HBOC will have no identifiable mutation after genetic testing. Here, we deploy a lasso-based model to combine serum miRNA profiles with clinical data to identify women at elevated risk for ovarian cancer among a population of 1831 individuals enrolled in an institutional biobank. The miRNA and metadata variables are mapped to two-dimensional space using lasso, after which a linear classification model is trained to estimate "BRCAness" and long-term risk of cancer. After tenfold cross-validation, the method offers a BRCA prediction AUC score of 0.98 (95% CI 0.94-1.0) and generalizes across subgroups stratified by age, cancer history, and racial/ethnic group. To demonstrate the clinical relevance of this phenotype, we use the lasso-based model to assess 5-year ovarian cancer risk among an independent cohort of 1044 subjects agnostic to genetic testing results enrolled in a randomized clinical trial. In this unselected population, the output of the lasso-based model strongly correlates to the log 5-year relative risk of ovarian cancer (R = 0.93, 95% CI 0.83-0.97, p < 0.0001). When the model was used to predict future onset of ovarian cancer directly, the AUC offered was AUC = 0.75 (95% CI 0.70-0.78). Together, these data suggest the proposed model is a predictor of future ovarian cancer risk.

Indexed as

Breast NeoplasmsHereditary Breast and Ovarian Cancer SyndromeMicroRNAsOvarian NeoplasmsAdultBRCA1 ProteinBRCA2 ProteinFemaleGenetic Predisposition to DiseaseGerm-Line MutationHumansMiddle AgedRisk FactorsBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanMicroRNAsBRCA1BRCA2LassomiRNAOvarian cancerRisk prediction

Identifiers

PMID41876608
PMCPMC13168662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.